Please use this identifier to cite or link to this item:
|Title:||Production of Alpha Emitters for Targeted Alpha Therapy|
|Authors:||MORGENSTERN Alfred; ABBAS Kamel; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos|
|Citation:||CURRENT RADIOPHARMACEUTICALS vol. 1 no. 3 p. 135-143|
|Publisher:||BENTHAM SCIENCE PUBL LTD|
|Type:||Articles in periodicals and books|
|Abstract:||Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in pre-clinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.|
|JRC Institute:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.